文献速递糖尿病

心脏应激与炎症标志物对2型糖尿病患者心力衰竭的预测:ADVANCE试验

Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial.
PubMed 文献 · Diabetes Care · 2017-07-06

在ADVANCE试验的3,098例2型糖尿病患者中开展巢式病例队列研究,评估NT-proBNP、hs-cTnT、IL-6和hs-CRP对心力衰竭发生或进展的预测价值。结果显示仅NT-proBNP在常规危险因素基础上持续且显著改善预测(C统计量0.8162升至0.8800),其余标志物联合或单独加入均未一致改善预测指标。

要点

  • NT-proBNP每升高1个标准差,心衰发生或进展风险HR为3.06(95%CI 2.37, 3.96)。
  • 将NT-proBNP加入常规危险因素模型后,5年风险预测C统计量由0.8162升至0.8800。
  • hs-cTnT、IL-6或hs-CRP联合或加入NT-proBNP后均未一致改善预测指标。

核心结论

  • 仅NT-proBNP在广泛临床危险因素和生物标志物之外,强烈且持续地改善2型糖尿病患者的心力衰竭预测。

研究设计与样本

  • 在ADVANCE试验的3,098例2型糖尿病患者中开展巢式病例队列研究。

主要发现

  • 校正主要危险因素后,各生物标志物升高均与心衰发生或进展风险升高显著相关。
  • NT-proBNP每升高1个标准差,心衰发生或进展的HR为3.06(95%CI 2.37, 3.96)。
  • hs-cTnT每升高1个标准差,HR为1.50(95%CI 1.27, 1.77)。
  • IL-6每升高1个标准差,HR为1.48(95%CI 1.27, 1.72)。
  • hs-CRP每升高1个标准差,HR为1.32(95%CI 1.12, 1.55)。

关键数值与推荐

  • 将NT-proBNP加入含常规危险因素的模型后,5年风险预测C统计量由0.8162升至0.8800。
  • 连续净重分类改善(NRI)为73.1%。
  • 分类NRI(5年风险<5%、5-10%、>10%)为24.2%。
  • hs-cTnT、IL-6或hs-CRP联合或加入NT-proBNP后,均未一致改善预测指标。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study examined the individual and combined effect of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), interleukin-6 (IL-6), and hs-CRP on the prediction of heart failure incidence or progression in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A nested case-cohort study was conducted in 3,098 participants with type 2 diabetes in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. RESULTS: A higher value of each biomarker was significantly associated with a higher risk of heart failure incidence or progression, after adjustment for major risk factors. The hazard ratios per 1-SD increase were 3.06 (95% CI 2.37, 3.96) for NT-proBNP, 1.50 (1.27, 1.77) for hs-cTnT, 1.48 (1.27, 1.72) for IL-6, and 1.32 (1.12, 1.55) for hs-CRP. The addition of NT-proBNP to the model including conventional risk factors meaningfully improved 5-year risk-predictive performance (C statistic 0.8162 to 0.8800; continuous net reclassification improvement [NRI] 73.1%; categorical NRI [<5%, 5-10%, >10% 5-year risk] 24.2%). In contrast, the addition of hs-cTnT, IL-6, or hs-CRP did not improve the prediction metrics consistently in combination or when added to NT-proBNP. CONCLUSIONS: Only NT-proBNP strongly and consistently improved the prediction of heart failure in patients with type 2 diabetes beyond a wide range of clinical risk factors and biomarkers.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Ohkuma T, Jun M, Woodward M, et al. Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial. Diabetes Care. 2017. PMID: 28684396. doi:10.2337/dc17-0509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。